

1 **RBC Invasion and invasion-inhibition assays using free merozoites isolated after**  
2 **cold treatment of *Babesia bovis* *in vitro* culture**

3

4 Takahiro Ishizaki <sup>a</sup>, Thillaiampalam Sivakumar <sup>a</sup>, Kyoko Hayashida <sup>a</sup>, Bumduuren  
5 Tuvshintulga <sup>a</sup>, Ikuo Igarashi <sup>a</sup>, and Naoaki Yokoyama <sup>a,\*</sup>

6

7 <sup>a</sup> *National Research Center for Protozoan Diseases, Obihiro University of Agriculture*  
8 *and Veterinary Medicine, Hokkaido 080-8555, Japan*

9

10 **\*Corresponding author:**

11 National Research Center for Protozoan Diseases, Obihiro University of Agriculture  
12 and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan.

13 Tel: +81-155-49-5649; Fax: 81-155-49-5643.

14 E-mail: yokoyama@obihiro.ac.jp

15

16

17 **Abstract**

18

19 *Babesia bovis* is an apicomplexan hemoprotozoan that can invade bovine red blood  
20 cells (RBCs), where it multiplies asexually. RBC invasion assays using free viable  
21 merozoites are now routinely used to understand the invasion mechanism of *B. bovis*,  
22 and to evaluate the efficacy of chemicals and antibodies that potentially inhibit RBC  
23 invasion by the parasite. The application of high-voltage pulses (high-voltage  
24 electroporation), a commonly used method to isolate free merozoites from infected  
25 RBCs, reduces the viability of the merozoites. Recently, a cold treatment of *B. bovis in*  
26 *vitro* culture was found to induce an effective release of merozoites from the infected  
27 RBCs. In the present study, we incubated *in vitro* cultures of *B. bovis* in an ice bath to  
28 liberate merozoites from infected RBCs and then evaluated the isolated merozoites in  
29 RBC invasion and invasion-inhibitions assays. The viability of the purified merozoites  
30 (72.4%) was significantly higher than that of merozoites isolated with high-voltage  
31 electroporation (48.5%). The viable merozoites prepared with the cold treatment also  
32 invaded uninfected bovine RBCs at a higher rate (0.572%) than did merozoites prepared  
33 with high-voltage electroporation (0.251%). The invasion-blocking capacities of

34 heparin, a polyclonal rabbit antibody directed against recombinant *B. bovis* rhoptry  
35 associated protein 1, and *B. bovis*-infected bovine serum were successfully  
36 demonstrated in an RBC invasion assay with the live merozoites prepared with the cold  
37 treatment, suggesting that the targets of these inhibitors were intact in the merozoites.  
38 These findings indicate that the cold treatment technique is a useful tool for the isolation  
39 of free, viable, invasion-competent *B. bovis* merozoites, which can be effectively used  
40 for RBC invasion and invasion-inhibition assays in *Babesia* research.

41

42 **Keywords:** *Babesia bovis*, Cold treatment, Invasion-inhibition assay, Merozoite  
43 isolation, RBC invasion

44

45 **1. Introduction**

46

47 *Babesia bovis*, an apicomplexan hemoprotozoan, causes severe clinical bovine  
48 babesiosis in cattle worldwide. The cattle disease caused by *B. bovis* is characterized by  
49 fever, hemoglobinuria, anemia, icterus, and neurological and respiratory syndromes,  
50 with occasional death (Bock et al., 2004; Everitt et al., 1986). *Babesia bovis*, which is  
51 biologically transmitted by ticks, has three different reproductive stages in its lifecycle:  
52 (i) gametogony, the sexual fusion of gametes within the mid-gut of the tick vector; (ii)  
53 sporogony, asexual reproduction in the salivary gland of the tick vector; and (iii)  
54 merogony, asexual reproduction in the erythrocytes (RBCs) of the infected animal  
55 (Homer et al., 2000).

56 The life cycle of *B. bovis* in cattle begins with the injection of the sporozoites by  
57 infected tick vectors while feeding on cattle blood (Hunfeld et al., 2008). The  
58 sporozoites directly invade the host RBCs, where they transform into merozoites and  
59 move into the merogony stage (Yokoyama et al., 2006). The rupture of the infected  
60 RBCs after the asexual multiplication of the parasite releases the mature merozoites,  
61 which then invade uninfected RBCs (Bock et al., 2004). The involvement of several

62 protozoan molecules secreted from the micronemes and rhoptries of *B. bovis* during  
63 merozoite invasion of RBCs, including merozoite surface antigens, rhoptry associated  
64 protein 1 (RAP-1), apical membrane antigen 1, and thrombospondin-related anonymous  
65 protein (Yokoyama et al., 2006), has been documented. Antisera directed against these  
66 protozoan antigens are reported to inhibit the asexual growth of the parasite *in vitro*  
67 (Gaffer et al., 2004a,b; Mosqueda et al., 2002a,b; Suarez et al., 2000; Yokoyama et al.,  
68 2002), but their exact roles in RBC invasion are not fully understood, hindering the  
69 development of an effective vaccine against this parasite. Other molecules that induce  
70 neutralizing antibodies against *B. bovis* are still being investigated (Silva et al., 2010;  
71 Suarez et al., 2011; Terkawi et al., 2013). *In vitro* invasion assays are essentially used to  
72 clarify the mechanism of RBC invasion, which involves parasite molecules (Sun et al.,  
73 2011). Similarly, invasion-inhibition assays (*in vitro* neutralization assays) are useful  
74 for investigating neutralizing antibodies raised against parasite antigens that are  
75 potential candidate vaccines (Gaffer et al., 2004a,b) or for analyzing the utility of  
76 invasion-blocking chemicals as possible chemotherapeutic agents against *B. bovis* (Bork  
77 et al., 2004; Nakamura et al., 2007; Okubo et al., 2007). High-quality, free, viable,

78 invasion-competent *B. bovis* merozoites are essential for both invasion and  
79 invasion-inhibition assays, if reliable results are to be obtained.

80 At present, two main methods are used to prepare free merozoites from *in vitro*  
81 cultures of *B. bovis*. With the first method, the merozoites are isolated from the  
82 supernatants of *in vitro* cultures (Hines et al., 1992; Rodriguez et al., 1986; Sun et al.,  
83 2011), whereas in the second method, the merozoites are released from RBCs  
84 physically ruptured by the application of high-voltage pulses (high-voltage  
85 electroporation) and collected (Franssen et al., 2003). Large volumes of *in vitro* cultures  
86 are required for the first method, to obtain sufficient free merozoites for RBC invasion  
87 assays, because the numbers of free merozoites in culture supernatants are very low  
88 (Suarez and McElwain, 2008; Sun et al., 2011). In contrast, large quantities of free  
89 merozoites can be obtained with high-voltage electroporation, but the viability of the  
90 merozoites is greatly affected by the harsh isolation method (Rodriguez et al., 2014).  
91 Therefore, the establishment of a new method is required to obtain large quantities of  
92 free, viable, invasion-competent merozoites from *in vitro* cultures of *B. bovis*.

93 A previous study reported that when *in vitro* cultures of *Babesia* parasites (*B.*

94 *divergens* and *B. major*) were stored at 4 °C, the paired form of the intraerythrocytic  
95 parasites was released into the culture medium as free merozoites (Konrad et al., 1985).  
96 Consistent with this observation, Rodriguez et al. (2014) reported the use of cold  
97 treatment to isolate free merozoites of *B. bovis*. However, the merozoites liberated by  
98 that group were not evaluated for their potential suitability for invasion and  
99 invasion-inhibition assays. Therefore, in the present study, *in vitro* cultures of *B. bovis*  
100 were subjected to cold treatment in an ice bath. The free merozoites released from the  
101 infected RBCs were purified and analyzed for their potential utility in RBC invasion  
102 and invasion-inhibition assays.  
103

104 **2. Materials and methods**

105

106 *2.1. In vitro culture of B. bovis*

107 *Babesia bovis* (Texas strain) was cultured in purified bovine RBCs in  
108 serum-free GIT medium (Wako, Osaka, Japan), as described previously (Bork et al.,  
109 2005). Parasite cultures with about 30% parasitemia were used to isolate *B. bovis*  
110 merozoites.

111

112 *2.2. Optimization of the duration of cold treatment and purification of free merozoites*

113 An aliquot (1 ml) of an *in vitro* culture of *B. bovis*, containing 100  $\mu$ l of RBCs  
114 (10% hematocrit), was subjected to cold treatment for 1, 2, 3, or 4 h in an ice bath. After  
115 treatment, each culture was resuspended in 10 ml of GIT medium, and slowly overlaid  
116 onto 2 ml of 30% (1.043 g/ml density) Percoll/phosphate-buffered saline (PBS) solution  
117 (GE Healthcare, Buckinghamshire, UK) at the bottom of a 50 ml centrifuge tube  
118 (Corning, Corning, NY, USA). The tubes were then centrifuged (Himac CF-9RX,  
119 Hitachi Koki, Tokyo, Japan) at  $280 \times g$  for 5 min at 4 °C, and then at  $330 \times g$  for 20 min.

120 An aliquot (10 ml) of the supernatant was transferred to a new tube and centrifuged at  
121  $1,500 \times g$  for 5 min at 4 °C. The resulting pellet, containing free merozoites, was  
122 washed twice with GIT medium and then suspended in 1 ml of GIT medium. The  
123 concentration of purified merozoites was determined with a disposable hemocytometer  
124 (AR Brown, Tokyo, Japan). The viability of the merozoites was assessed with  
125 6-carboxyfluorescein diacetate (6-CFDA; Invitrogen Corp., Carlsbad, CA, USA), which  
126 stains only live merozoites, and propidium iodide (PI; Dojindo, Kumamoto, Japan),  
127 which stains both live and dead merozoites, as described previously (McElwain et al.,  
128 1987; Zotta et al., 2012). Briefly, 100  $\mu$ l of merozoite-containing GIT was mixed with  
129 6-CFDA and PI at final concentrations of 50  $\mu$ M and 20  $\mu$ M, respectively, and  
130 incubated at room temperature for 15 min. After the samples were washed with PBS,  
131 the numbers of total (both live and dead merozoites) and the numbers of live merozoites  
132 were counted with a disposable hemocytometer under a fluorescence microscope  
133 (Keyence, Osaka, Japan) to calculate the viability of the merozoites.

134

135 *2.3. Dynamics of intraerythrocytic parasite stages during cold treatment*

136           An aliquot (1 ml) of *B. bovis in vitro* culture, containing 100 µl of RBCs, was  
137 incubated in an ice bath or at 37°C for 1, 2, 3, or 4 hours. Erythrocyte smears prepared  
138 at the each time point of incubation were stained with Giemsa and observed under a  
139 light microscope to determine the percentages of paired and single parasite stages  
140 within the erythrocytes. The experiment was repeated thrice.

141

142   2.4. Comparison of RBC invasion efficiencies of free merozoites obtained with cold  
143 treatment or high-voltage electroporation

144           The efficiencies of the free merozoites of *B. bovis* obtained with cold  
145 treatment or electroporation in invading fresh RBCs *in vitro* were analyzed and  
146 compared. *Babesia bovis* cultures (100 µl) with 30% parasitemia were incubated on ice  
147 for the optimal time. The liberated free merozoites were purified and their viability  
148 analyzed, as described in section 2.2. *Babesia bovis*-infected RBCs sourced from the  
149 same *in vitro* culture were also used to isolate the merozoites by the application of  
150 high-voltage pulses, as described previously, with minor modifications (Franssen et al.,  
151 2003; Sun et al., 2011). Briefly, 100 µl of *B. bovis*-infected RBCs with 30% parasitemia

152 were mixed with 300  $\mu$ l of GIT medium. The mixture was added to a 0.2 cm cuvette  
153 (Bio-Rad, Hercules, CA, USA) and subjected to five intermittent (10 s, 0 °C),  
154 high-voltage pulses (1.5 kV, 400  $\Omega$ , 25  $\mu$ F) with a Bio-Rad Gene Pulser II to rupture the  
155 RBCs. The mixture was then washed three times with GIT medium to eliminate the  
156 debris from the burst RBCs. The viability of the free merozoites was determined as  
157 described in section 2.2.

158           To assess and compare the RBC invasion efficiencies of the isolated  
159 merozoites, 50  $\mu$ l of an uninfected bovine erythrocyte mass, containing  $2.21 \times 10^6$   
160 RBCs, was added to 1 ml of GIT medium containing  $9.28 \times 10^6$  free viable merozoites  
161 (at a multiplicity of infection [MOI] of 4.2) isolated with the cold treatment or  
162 electroporation, in triplicate in 24-well plates (Thermo Scientific, K. K., Waltham, MA,  
163 USA), and incubated in an atmosphere of 5% CO<sub>2</sub> and 5% O<sub>2</sub> at 37 °C. Thin blood  
164 smears were prepared after incubation for 5, 20, or 60 min, and the percentage  
165 parasitemia was determined with light microscopy, based on the numbers of parasitized  
166 RBCs in 5,000 total RBCs (Bork et al., 2005).

167

168 2.5. RBC invasion-inhibition assays

169

170 2.5.1. Invasion-inhibition assay using heparin

171 Heparin, which is reported to inhibit the invasion of *B. bovis* (Bork et al.,  
172 2004), was used to assess whether the merozoites obtained with the cold treatment were  
173 suitable for invasion-inhibition assays to investigate invasion-blocking chemicals.  
174 Uninfected bovine RBCs (50 µl) were added to GIT medium containing 4, 20, or 100  
175 units (U) of heparin sodium (Wako) and purified free merozoites at an MOI of 4.2, in  
176 triplicate in a 24-well plate, as described in section 2.3. The cultures were incubated,  
177 and the percentage parasitemia was determined after incubation for 60 min.

178

179 2.5.2. Invasion-inhibition assays using *B. bovis*-specific antibodies

180 Two kinds of antibodies, an antiserum raised in a rabbit against recombinant  
181 *B. bovis* RAP-1 (rRAP-1) and serum from a cow experimentally infected with *B. bovis*,  
182 were used in this study to assess whether the merozoites isolated with the cold treatment  
183 can be used effectively in invasion-inhibition assays to investigate *B. bovis*-specific

184 neutralizing antibodies. Recombinant RAP-1 was expressed and purified as a  
185 glutathione *S*-transferase (GST) fusion protein (GST-rRAP-1), as described previously  
186 (Yokoyama et al., 2002). Japanese white rabbits (CLEA, Tokyo, Japan) were  
187 immunized with the GST-rRAP-1 or GST antigen (control) to produce polyclonal  
188 antibodies (rabbit anti-GST-rRAP-1 or rabbit anti-GST, respectively), with a previously  
189 described method (Terkawi et al., 2013). The serum from a cow experimentally infected  
190 with *B. bovis* was described in a previous report (Terkawi et al., 2011). Immunization  
191 experiments in animals were conducted in accordance with the standards for the care  
192 and management of experimental animals stipulated by the Obihiro University of  
193 Agriculture and Veterinary Medicine, Hokkaido, Japan.

194           In the RBC invasion-inhibition assays performed in triplicate in a 96-well  
195 plate, uninfected bovine RBCs were added to GIT medium containing rabbit  
196 anti-GST-rRAP-1 immune serum (diluted 1:100, 1:500, or 1:1000) or experimentally  
197 infected *B. bovis* bovine serum (diluted 1:100, 1:500, or 1:2500) with purified free  
198 merozoites at an MOI of 4.2. Medium without serum, medium with rabbit anti-GST,  
199 and medium with uninfected bovine serum were used as the negative controls. The

200 percentage parasitemia in each culture was determined after incubation for 60 min, and

201 then compared with those of the corresponding controls.

202

203 *2.6. Statistical analyses*

204 All data were analyzed with an independent-samples Student's *t* test. *P* values <

205 0.05 were considered statistically significant.

206

207

208 **3. Results**

209

210 *3.1. Isolation of free viable merozoites with cold treatment*

211 *In vitro* cultures of *B. bovis* were incubated for 1–4 hours in an ice bath to  
212 induce the release of free merozoites from the infected RBCs. The merozoites liberated  
213 from the RBCs were purified with Percoll-gradient centrifugation, and the numbers of  
214 viable merozoites were counted. The results confirmed that the cold treatment released  
215 free viable merozoites from the infected RBCs, and that the maximum number of viable  
216 merozoites was obtained after ice-bath incubation for 2 h (Fig. S1). When the cultures  
217 were incubated for more than 2 h, the viable merozoite counts declined with time.  
218 Therefore, a period of 2 h was considered optimal for the ice-bath treatment, and was  
219 used in subsequent experiments involving cold-treatment-based merozoite isolation.

220 The viability of the merozoites isolated with the cold treatment or  
221 high-voltage electroporation was compared. The viability of the merozoites isolated  
222 with the cold treatment (72.4%) was much higher than the viability of those isolated  
223 with high-voltage electroporation (48.5%;  $P < 0.05$ ).

224           When the *in vitro* culture was incubated in an ice bath for 2 or more hours,  
225 the percentage of paired merozoites within erythrocytes significantly decreased as  
226 compared to that determined at 0-hour incubation (Table 1). Therefore, the percentage  
227 of single forms relatively increased during cold treatment. In contrast, such differences  
228 were not observed in culture that had been incubated at 37°C.

229

230 *3.2. RBC invasion assays using viable merozoites prepared with cold treatment or*  
231 *high-voltage electroporation*

232           The free *B. bovis* merozoites prepared with cold treatment or high-voltage  
233 electroporation were incubated with uninfected bovine RBCs in GIT medium, and  
234 parasitemia was monitored at different time points (5, 20, and 60 min) to determine the  
235 invasion efficiencies of the merozoites. The parasitemia in the cultures initiated with  
236 free merozoites obtained with both methods gradually increased with increasing  
237 incubation time, but the merozoites released by the cold treatment caused significantly  
238 greater parasitemia at all the time points examined than did those liberated with  
239 high-voltage electroporation ( $P < 0.05$ ; Fig. 1). Consistent with these observations, the

240 invasion efficiency of the viable merozoites isolated with the cold treatment (0.572%)  
241 was higher than that of the merozoites isolated with high-voltage electroporation  
242 (0.251%), when calculated from the MOI (4.2) and the 60 min parasitemia values.

243

### 244 3.3 Invasion-inhibition assays using invasion-blocking agents

245 To confirm the potential utility of the free merozoites liberated with the cold  
246 treatment in the *in vitro* assays used to screen chemical and biological agents that may  
247 inhibit RBC invasion by *B. bovis* merozoites, invasion-inhibition assays were performed  
248 using heparin or *B. bovis*-specific antibodies. RBC invasion by the free viable  
249 merozoites prepared with the cold treatment was significantly inhibited by 4–100 U of  
250 heparin but not in the control cultures, which contained no heparin ( $P < 0.05$ ; Fig. 2A).  
251 When rabbit anti-GST-rRAP-1 antiserum and the *B. bovis*-infected bovine serum were  
252 analyzed in the invasion-inhibition assays with free merozoites isolated with the cold  
253 treatment, RBC invasion by the merozoites was significantly inhibited by both sera at  
254 low dilutions (1:100) compared with the controls (Figs. 2B and 2C, respectively),  
255 suggesting that the free merozoites prepared with the cold treatment can be effectively

256 used to screen chemical and biological agents that inhibit RBC invasion by *B. bovis*.

257

258

259 **4. Discussion**

260

261           The currently available methods used to isolate free, viable merozoites, which  
262 are essential for RBC invasion and invasion-inhibition assays, are constrained by either  
263 the requirement for a large volume of *in vitro* culture or the low viability of the  
264 merozoites obtained (Rodriguez et al., 2014; Suarez and McElwain, 2008; Sun *et al.*,  
265 2011). On the other hand, the cold treatment method reported by Rodriguez et al. (2014)  
266 could be an alternative technique to obtain free, viable *B. bovis* merozoites. However,  
267 the merozoites liberated by cold treatment were not evaluated for their utility in RBC  
268 invasion and invasion-inhibition assays. Therefore, in the present study, we analyzed  
269 the suitability of the free merozoites prepared with the cold treatment for RBC invasion  
270 and invasion-inhibition assays.

271           When *in vitro* cultures of *B. bovis* were incubated in an ice bath for 1–4 h, the  
272 number of free viable merozoites isolated increased steadily for 2 h, after which a  
273 significant reduction was observed, suggesting that the viability of the free merozoites  
274 released into the culture medium was affected by exposure to cold for more than 2 h.  
275 Therefore, 2 h was considered the optimal duration of the cold treatment (Rodriguez et

276 al., 2014). We then compared the viability of free merozoites isolated with the cold  
277 treatment or high-voltage electroporation. In agreement with Rodriguez et al. (2014),  
278 the viability of the cold-isolated merozoites was significantly higher than that of  
279 merozoites isolated with high-voltage pulses. The physical damage caused by the  
280 high-voltage pulses could explain the lower viability of these liberated merozoites  
281 (Rodriguez et al., 2014).

282           We also analyzed the ratio of different morphological forms of the parasite in  
283 the RBCs before and after the cold treatment, and found that the paired merozoites  
284 decreased significantly after the cold treatment, while the single forms relatively  
285 increased. This suggests that the cold treatment induces the preferential release of the  
286 paired merozoites, which are ready to egress and invade new RBCs (Konrad et al.,  
287 1985). In contrast, although large numbers of merozoites can be obtained with  
288 high-voltage electroporation, different morphological forms, including immature stages  
289 and dead parasites, are invariably released with this technique, resulting in a low  
290 viability of isolated merozoites. This could also explain why the merozoites isolated  
291 with the cold treatment invaded the RBCs more efficiently than those isolated with

292 high-voltage electroporation, even though the viable merozoites prepared with both  
293 methods were added to the culture at the same MOIs. Furthermore, even the paired  
294 merozoites liberated by high-voltage pulses may not invade the RBCs effectively,  
295 because their membrane properties may have been altered by the harsh treatment.

296           Having confirmed the viability and RBC invasion efficacy of the free  
297 merozoites prepared with the cold treatment, we tested whether these merozoites can be  
298 effectively used for RBC invasion-inhibition assays, which are used widely to  
299 investigate invasion-blocking chemicals and to analyze the antibodies raised against  
300 candidate vaccine antigens. Lower parasitemia was observed in cultures containing  
301 heparin or antibodies directed against *B. bovis* than in the corresponding controls,  
302 suggesting that the targets of these inhibitors are intact in the merozoites prepared with  
303 the cold treatment and that they can therefore be effectively used in invasion-inhibition  
304 assays.

305           In summary, the cold treatment technique, which unlike high-voltage  
306 electroporation requires no sophisticated equipment, is an effective tool with which to  
307 prepare large quantities of free, viable, invasion-competent merozoites from *in vitro*

308 cultures of *B. bovis*. The merozoites obtained with this method are well suited to the  
309 RBC invasion and invasion-inhibition assays. Therefore, the cold treatment will  
310 facilitate research into the mechanism of RBC invasion by *B. bovis*, novel candidate  
311 vaccines, and invasion-blocking chemicals, allowing the development of improved  
312 control and preventive strategies for *B. bovis*.

313

314

315 **Acknowledgements**

316

317           This study was supported by grants from the Science and Technology

318 Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry,

319 and from the JSPS KAKENHI (grant numbers: 15H00891, 15K14862, and 25660235).

320

321 **References**

322

323 Bock, R.E., Jackson, L., de Vos, A., Jorgensen, W., 2004. Babesiosis of cattle.  
324 Parasitology 129 (Suppl), S247–S269.

325

326 Bork, S., Okamura, M., Matsuo, T., Kumar, S., Yokoyama, N., Igarashi, I., 2005. Host  
327 serum modifies the drug susceptibility of *Babesia bovis in vitro*. Parasitology. 2005,  
328 130, 489–492.

329

330 Bork, S., Yokoyama, N., Ikehara, Y., Kumar, S., Sugimoto, C., Igarashi, I., 2004.  
331 Growth-inhibitory effect of heparin on *Babesia* parasites. Antimicrob. Agents  
332 Chemother. 48, 236–241.

333

334 Everitt, J.I., Shadduck, J.A., Steinkamp, C., Clabaugh, G., 1986. Experimental *Babesia*  
335 *bovis* infection in Holstein calves. Vet. Pathol. 23, 556–62.

336

337 Franssen, F.F., Gaffar, F.R., Yatsuda, A.P., de Vries, E., 2003. Characterisation of  
338 erythrocyte invasion by *Babesia bovis* merozoites efficiently released from their host  
339 cell after high-voltage pulsing. Microbes Infect. 5, 365–372.

340

341 Gaffar, F.R., Yatsuda, A.P., Franssen, F.F., de Vries, E., 2004a. Erythrocyte invasion by  
342 *Babesia bovis* merozoites is inhibited by polyclonal antisera directed against peptides

343 derived from a homologue of *Plasmodium falciparum* apical membrane antigen 1.  
344 Infect. Immun. 72, 2947–2955.  
345  
346 Gaffar, F.R., Yatsuda, A.P., Franssen, F.F., de Vries, E., 2004b. A *Babesia bovis*  
347 merozoite protein with a domain architecture highly similar to the  
348 thrombospondin-related anonymous protein (TRAP) present in *Plasmodium* sporozoites.  
349 Mol. Biochem. Parasitol. 136, 25–34.  
350  
351 Hines, S.A., Palmer, G.H., Jasmer, D.P., McGuire, T.C., McElwain, T.F., 1992.  
352 Neutralization-sensitive merozoite surface antigens of *Babesia bovis* encoded by  
353 members of a polymorphic gene family. Mol. Biochem. Parasitol. 55, 85–94.  
354  
355 Homer, M.J., Aguilar-Delfin, I., Telford, S.R., Krause, P.J., Persing, D.H., 2000.  
356 Babesiosis. Clin. Microbiol. Rev. 13, 451–469.  
357  
358 Hunfeld, K.P., Hildebrandt, A., Gray, J.S., 2008. Babesiosis: recent insights into an  
359 ancient disease. Int. J. Parasitol. 38, 1219–1237.  
360  
361 Konrad, J., Canning, E.U., Phipps, L.P., Donnelly, J., 1985. Maintenance of *in vitro*  
362 cultures of *Babesia divergens* and *Babesia major* at low temperatures. Z. Parasitenkd.  
363 71, 313–316.  
364

365 McElwain, T.F., Perryman, L.E., Davis, W.C., McGuire, T.C., 1987. Antibodies define  
366 multiple proteins with epitopes exposed on the surface of live *Babesia bigemina*  
367 merozoites. J. Immunol. 138, 2298–2304.

368

369 Mosqueda, J., McElwain, T.F., Palmer, G.H., 2002a. *Babesia bovis* merozoite surface  
370 antigen 2 proteins are expressed on the merozoite and sporozoite surface, and specific  
371 antibodies inhibit attachment and invasion of erythrocytes. Infect. Immun. 70,  
372 6448–6455.

373

374 Mosqueda, J., McElwain, T.F., Stiller, D., Palmer, G.H., 2002b. *Babesia bovis*  
375 merozoite surface antigen 1 and rhoptry-associated protein 1 are expressed in  
376 sporozoites, and specific antibodies inhibit sporozoite attachment to erythrocytes. Infect.  
377 Immun. 70, 1599–1603.

378

379 Nakamura, K., Yokoyama, N., Igarashi, I., 2007. Cyclin-dependent kinase inhibitors  
380 block erythrocyte invasion and intraerythrocytic development of *Babesia bovis* *in vitro*.  
381 Parasitology 134, 1347–1353.

382

383 Okubo, K., Yokoyama, N., Govind, Y., Alhassan, A., Igarashi, I., 2007. *Babesia bovis*:  
384 effects of cysteine protease inhibitors on *in vitro* growth. Exp. Parasitol. 117, 214–217.

385

386 Rodriguez, S.D., Buening, G.M., Vega, C.A., Carson, C.A., 1986. *Babesia bovis*:

387 purification and concentration of merozoites and infected bovine erythrocytes. *Exp.*  
388 *Parasitol.* 61, 236–43.

389

390 Rodriguez, A.E., Florin-Christensen, M., Flores, D.A., Echaide, I., Suarez, C.E.,  
391 Schnittger, L., 2014. The glycosylphosphatidylinositol-anchored protein repertoire of  
392 *Babesia bovis* and its significance for erythrocyte invasion. *Ticks Tick Borne Dis.* 5,  
393 343–348.

394

395 Silva, M.G., Ueti, M.W., Norimine, J., Florin-Christensen, M., Bastos, R.G., Goff, W.L.,  
396 Brown, W.C., Oliva, A., Suarez, C.E., 2010. *Babesia bovis* expresses a  
397 neutralization-sensitive antigen that contains a microneme adhesive repeat (MAR)  
398 domain. *Parasitol. Int.* 59, 294–297.

399

400 Suarez, C.E., Florin-Christensen, M., Hines, S.A., Paler, G.H., Brown, W., McElwain,  
401 T.F., 2000. Characterization of allelic variation in the *Babesia bovis* merozoite surface  
402 antigen (MSA-1) locus and identification of a cross-reactive inhibition-sensitive MSA-1  
403 epitope. *Infect. Immun.* 68, 6665–6670.

404

405 Suarez, C.E., Laughery, J.M., Bastos, R.G., Johnson, W.C., Norimine, J., Asenzo, G.,  
406 Brown, W.C., Florin-Christensen, M., Goff, W.L., 2011. A novel neutralization  
407 sensitive and subdominant RAP-1-related antigen (RRA) is expressed by *Babesia bovis*  
408 merozoites. *Parasitology* 138, 809–818.

409

410 Suarez, C.E., McElwain, T.F., 2008. Transient transfection of purified *Babesia bovis*  
411 merozoites. *Exp. Parasitol.* 118, 498–504.

412

413 Sun, Y., Moreau, E., Chauvin, A., Malandrin, L., 2011. The invasion process of bovine  
414 erythrocyte by *Babesia divergens*: knowledge from an *in vitro* assay. *Vet. Res.* 42, 62.

415

416 Terkawi, M.A., Huyen, N.X., Wibowo, P.E., Seuseu, F.J., Aboulaila, M., Ueno, A., Goo,  
417 Y.K., Yokoyama, N., Xuan, X., Igarashi, I., 2011. Spherical body protein 4 is a new  
418 serological antigen for global detection of *Babesia bovis* infection in cattle. *Clin.*  
419 *Vaccine Immunol.* 18, 337–342.

420

421 Terkawi, M.A., Ratthanophart, J., Salama, A., AbouLaila, M., Asada, M., Ueno, A.,  
422 Alhasan, H., Guswanto, A., Masatani, T., Yokoyama, N., Nishikawa, Y., Xuan, X.,  
423 Igarashi, I., 2013. Molecular characterization of a new *Babesia bovis*  
424 thrombospondin-related anonymous protein (BbTRAP2). *PLoS One.* 8, e83305.

425

426 Yokoyama, N., Okamura, M., Igarashi, I., 2006. Erythrocyte invasion by *Babesia*  
427 parasites: current advances in the elucidation of the molecular interactions between the  
428 protozoan ligands and host receptors in the invasion stage. *Vet. Parasitol.* 138, 22–32.

429

430 Yokoyama, N., Suthisak, B., Hirata, H., Matsuo, T., Inoue, N., Sugimoto, C., Igarashi,

431 I., 2002. Cellular localization of *Babesia bovis* merozoite rhoptry-associated protein 1  
432 and its erythrocyte-binding activity. *Infect. Immun.* 70, 5822–5826.

433

434 Zotta, T., Guidone, A., Tremonte, P., Parente, E., Ricciardi, A., 2012. A comparison of  
435 fluorescent stains for the assessment of viability and metabolic activity of lactic acid  
436 bacteria. *World J. Microbiol. Biotechnol.* 28, 919–927.

437

438

439

440 **Figure Legends**

441

442 **Fig. 1. Comparison of RBC invasion efficiencies of free viable merozoites prepared**

443 **with the cold treatment or high-voltage electroporation.** Free viable merozoites

444 prepared with the cold treatment or high-voltage electroporation were added in triplicate

445 to culture plates containing uninfected bovine RBCs at MOI = 4.2. The percentage

446 parasitemia of the cultures was measured after incubation for 5, 20, and 60 min. The

447 asterisks indicate that the parasitemia in cultures initiated with merozoites prepared with

448 the cold treatment was significantly higher ( $P < 0.05$ ) at all three time points than that

449 of cultures initiated with merozoites obtained with high-voltage electroporation,

450 indicating that the merozoites prepared with the former method invaded the RBCs more

451 efficiently than those obtained with the latter technique.

452


453 **Fig. 2. RBC invasion-inhibition assays using free viable merozoites obtained with**

454 **the cold treatment.** The suitability of free viable merozoites prepared with the cold


455 treatment for RBC invasion-inhibition assays was assessed using heparin (A), rabbit

456 anti-GST-rRAP-1 antiserum (B), and *B. bovis*-infected bovine serum (C). Uninfected

457 bovine RBCs were incubated (at MOI = 4.2) in duplicate with free merozoites prepared  
458 with the cold treatment in the presence of 4, 20, or 100 U of heparin (**A**), rabbit  
459 anti-GST-rRAP-1 (diluted 1:100, 1:500, or 1:1000) or rabbit anti-GST antiserum  
460 (diluted 1:100) (**B**), or *B. bovis*-infected bovine serum (diluted 1:100, 1:500, or 1:2500)  
461 or uninfected bovine serum (diluted 1:100) (**C**). Culture medium containing no inhibitor  
462 was also used as a control. Parasitemia was determined after incubation for 60 min.  
463 Data are expressed as the percentage of the mean parasite growth rate relative to that in  
464 the control culture without inhibitors. The asterisks indicate that the relative growth  
465 rates were significantly reduced ( $P < 0.05$ ) by heparin (4–100 U), rabbit  
466 anti-GST-rRAP-1 antiserum (1:100), and *B. bovis*-infected serum (1:100) compared  
467 with the growth rates of the corresponding controls, indicating that RBC invasion by the  
468 merozoites was inhibited by heparin and by the specific antibodies directed against *B.*  
469 *bovis*.  
470



**Fig. 1**



**Fig. 2**

**Table 1.** The changes in the percentage of paired and single stages of *B. bovis* within the erythrocytes during the incubation of *in vitro* cultures in ice bath

Hours post-incubation	Intraerythrocytic stages (%) <sup>a</sup>		SD <sup>b</sup>	<i>P</i> value <sup>c</sup>
	Paired	Single		
<b>Ice-bath incubation</b>				
0	46.41	53.59	2.01	
1	43.14	56.86	0.93	0.104
2	39.66	60.34	1.12	0.014 <sup>d</sup>
3	40.84	59.16	1.86	0.045 <sup>d</sup>
4	39.15	60.85	0.44	0.007 <sup>d</sup>
<b>37°C incubation<sup>e</sup></b>				
0	45.75	54.25	2.87	
1	45.99	54.01	3.28	0.940
2	45.07	54.93	2.58	0.815
3	44.42	55.58	1.11	0.576
4	45.37	54.63	1.16	0.873



<sup>a</sup> Giemsa-stained erythrocyte smears prepared at each time point of incubation were observed under a light microscope to determine the percentage of paired and single parasite stages.

<sup>b</sup> SD, Standard deviation

<sup>c</sup> *P* values were calculated as compare to 0-hour incubation.

<sup>d</sup> The percentage of paired merozoites within the erythrocytes significantly decreased ( $P < 0.05$ ) in *in vitro* cultures incubated in ice-bath for 2 or more hours.

<sup>e</sup> The percentages of paired as well as single parasite stages did not change with time when the *in vitro* cultures were incubated at 37°C for 4 hours.

**A****B**

**Fig. S1. Cold-treatment-induced release of free viable *B. bovis* merozoites from infected RBCs.** **Panel A:** A light microscopic image of a Giemsa-stained thin blood smear prepared from an *in vitro* culture of *B. bovis* that was subjected to cold treatment in an ice bath for 2 h, showing the release of free merozoites. Arrows indicate free merozoites found inside and outside the RBC ghosts. **Panel B:** Total number of free viable merozoites purified with Percoll-gradient centrifugation from 100 ml of RBCs from *in vitro* cultures of *B. bovis* after incubation in an ice bath for 1, 2, 3, or 4 h. The asterisk indicates that the highest number of free viable merozoites was isolated from the culture incubated in the ice bath for 2 h, compared with those incubated for 0, 1, 3, or 4 h ( $P < 0.05$ ).